Abstract Body

Background

MVA-BN vaccination is now considered the primary preventive measure against mpox infection. A booster dose administered at least two years after the primary vaccination significantly enhances both humoral and cellular immunity. Assessing whether the subcutaneous (SC) or intradermal (ID) administration route influences the magnitude of the response may inform public health strategies for maximizing dose savings.

Methods

We conducted a prospective observational study in individuals who had completed a two-dose primary MVA-BN vaccination cycle and received a booster dose either subcutaneously (SC, 0.5 mL) or intradermally (ID, 0.1 mL) two years after. Individuals who had previously received the smallpox vaccine were excluded from analysis. Blood samples were collected at the time of booster administration (T1) and after 4 weeks (T2). Anti-MPXV IgG titers were measured by immunofluorescence assay (IFA, clade IIb), neutralizing antibodies (nAb) by PRNT50 (clade IIb), and MVA-responsive T-cells by IFN-γ ELISpot. Clinical and immunological features were compared between SC and ID groups using the Wilcoxon paired and Mann-Whitney tests.

Results

Among the 56 participants included, 34 (61%) received SC and 22 (39%) ID. All individuals were males, with a median age of 43.7 years [IQR 36.6–50.0]; 8 of them (14%) were people with HIV (PWH). From T1 to T2, IgG titers increased significantly in both SC and ID groups (p < 0.001). Reactive sera varied from 47% to 100% in SC and 59% to 100% in ID. No evidence for a difference was found between groups in the increase in IgG titers. Additionally, nAb titers significantly increased from T1 to T2 (p < 0.0001), with reactivity ranging from 6% to 77% for SC and from 23% to 91% for ID. Comparison between groups showed a significant advantage for ID over SC in the increase of nAb titers (p = 0.0002) (Figure 1A). MVA-specific T-cell response also improved from baseline to one month after administration in both the SC (p<0.0001) and ID (p<0.002) groups. No evidence was found for a difference in response variation between the two groups (Figure 1B).

Conclusions

Both subcutaneous and intradermal routes of administration of the MVA-BN booster dose elicit strong humoral and cellular responses, with a clear advantage for the intradermal route in improving the neutralising response. These results support the use of the intradermal route for booster administration to conserve vaccine resources and optimize the possibilities for intervention in high-risk populations.

Table or Figure